Myriad Genetics Q1 2022 revenue $164.9M, GAAP EPS -$0.26, adjusted EPS -$0.03; reiterates FY2022 guidance

MYRIAD GENETICS INC

2022-Q1 EPS reported -$0.26 revenue$164,900,000

Revenue $164.9M (+11% YoY ex-divested); GAAP EPS $(0.26) improved from $(0.52); adjusted EPS $(0.03) from $(0.06).
Cash $339.2M, no debt; adjusted gross margin 71.1%, operating loss $2.8M improved from $3.3M.
Segment: Hereditary cancer rev $70.9M (-7% YoY); Pharmacogenomics rev $29.3M (+66% YoY); Prenatal +35%.
Reiterated FY2022 guidance: rev $670-700M; GAAP EPS $(0.90)-(0.70); adj EPS $0.00-$0.20.
Launched Precise Tumor test, expanded MyRisk to 13 genes, partnered on liquid biopsy test.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.